B
BIA Separations
A worldwide provider of solutions for biopharmaceutical companies
About BIA Separations
BIA Separations specializes in the development and manufacturing of Convective Interaction Media (CIM) monolithic chromatographic columns, which are essential for the production, purification, and analytics of large biomolecules. The company serves clients in the biopharmaceutical industry, including those involved in gene therapy, vaccine production, and mRNA technologies. Operating in the biotechnology market, BIA Separations employs a business model that focuses on selling high-performance chromatography tools and providing technical support and process development services. Revenue is generated through the direct sale of their proprietary monolithic columns and associated services. The company has been integrated into Sartorius, enhancing its portfolio in gene therapy and vaccine solutions.
Source: Dealroom company dataAt a glance
- Founded
- 1998
- Headquarters
- Wilmington, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Eureka
Series A1 investor entered at this stage
META
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about BIA Separations on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BIA Separations on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.